Brief: Resverlogix announces second positive recommendation for Apabetalone (RVX-208) Phase 3 study
05/12/2016 17:13
Dec 5 (Reuters) - Resverlogix Corp RVX.TO :
* Press release - Resverlogix announces second positive
recommendation from Data Safety Monitoring Board for Phase 3
study of Apabetalone (RVX-208)
* Data and Safety Monitoring Board reviewed available study
data and noted that no safety or efficacy concerns were
identified
* "First patients in trial have now surpassed one year mark
and Apabetalone remains well-tolerated with a consistent safety
profile."
* Data and Safety Monitoring Board for Co's Phase 3
BETonMACE trial recommended that study to continue as planned
without any modifications
Source text for Eikon: ID:nPn8CvfKPa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment